ea0016s30.6 | Clinical highlights | ECE2008
, Andersen Marianne
, Hagen Claus
, Heickendorff Lene
, Hermann Anne Pernille
Background: PPARγ-agonist treatment may decrease bone mineral density (BMD) in postmenopausal women. The hypothesis that premenopausal women are relatively protected from mineral loss during PPARγ-agonist treatment has not been evaluated in clinical studies.Aim: To investigate the effect of pioglitazone on BMD and bone turnover markers in patients with polycystic ovary syndrome (PCOS).Methods: Thirty premenopausal PCOS pa...